Play all audios:
ABSTRACT External beam radiotherapy (EBRT) is an important cornerstone in the treatment of localized prostate cancer. Current image-guided radiotherapy (IGRT) techniques allow for more
accurate and precise delivery of radiation treatment by the use of imaging before each fraction. Magnetic resonance guided radiotherapy (MRgRT) is the next step in IGRT with hybrid systems
combining linear accelerators with MRI-scanners. With MRgRT, it is possible to visualize pelvic anatomy in great detail and subsequently perform replanning of the radiation dose distribution
before each radiotherapy fraction. This technique has the potential to increase the therapeutic window of EBRT, by improved normal tissue sparing due to margin reduction and more accurate
target dose delivery. This is particularly promising for prostate cancer, with its biology lending itself to ultra-hypofractionation, reducing radiotherapy treatment to as little as five
fractions. Also, recent studies have shown that focal dose escalation to the intraprostatic tumor to high ablative doses can substantially increase disease-free survival. In this article, we
discuss these unique opportunities as well as the potential future benefits of MRgRT in prostate cancer treatment. Access through your institution Buy or subscribe This is a preview of
subscription content, access via your institution ACCESS OPTIONS Access through your institution Subscribe to this journal Receive 4 print issues and online access $259.00 per year only
$64.75 per issue Learn more Buy this article * Purchase on SpringerLink * Instant access to full article PDF Buy now Prices may be subject to local taxes which are calculated during checkout
ADDITIONAL ACCESS OPTIONS: * Log in * Learn about institutional subscriptions * Read our FAQs * Contact customer support SIMILAR CONTENT BEING VIEWED BY OTHERS ULTRA-HYPOFRACTIONATION FOR
NODE-POSITIVE PROSTATE CANCER: PUSHING BOUNDARIES AND REDEFINING STANDARDS Article Open access 08 May 2025 COMPARATIVE EFFECTIVENESS OF LOW-DOSE-RATE BRACHYTHERAPY WITH OR WITHOUT EXTERNAL
BEAM RADIOTHERAPY IN FAVORABLE AND UNFAVORABLE INTERMEDIATE-RISK PROSTATE CANCER Article Open access 30 June 2022 CONVENTIONAL DOSE VERSUS DOSE ESCALATED RADIOTHERAPY INCLUDING
HIGH-DOSE-RATE BRACHYTHERAPY BOOST FOR PATIENTS WITH GLEASON SCORE 9–10 CLINICAL LOCALIZED PROSTATE CANCER Article Open access 07 January 2022 REFERENCES * Zelefsky MJ, Kollmeier M, Cox B,
Fidaleo A, Sperling D, Pei X, et al. Improved clinical outcomes with high-dose image guided radiotherapy compared with non-IGRT for the treatment of clinically localized prostate cancer. Int
J Radiat Oncol Biol Phys. 2012;84:125–9. Article PubMed Google Scholar * Raaymakers BW, Jurgenliemk-Schulz IM, Bol GH, Glitzner M, Kotte A, van Asselen B, et al. First patients treated
with a 1.5 T MRI-Linac: clinical proof of concept of a high-precision, high-field MRI guided radiotherapy treatment. Phys Med Biol. 2017;62:L41–50. Article CAS PubMed Google Scholar *
Fischer-Valuck BW, Henke L, Green O, Kashani R, Acharya S, Bradley JD, et al. Two-and-a-half-year clinical experience with the world’s first magnetic resonance image guided radiation therapy
system. Adv Radiat Oncol. 2017;2:485–93. Article PubMed PubMed Central Google Scholar * Kerkmeijer LGW, Groen VH, Pos FJ, Haustermans K, Monninkhof EM, Smeenk RJ, et al. Focal boost to
the intraprostatic tumor in external beam radiotherapy for patients with localized prostate cancer: results from the FLAME randomized phase III trial. J Clin Oncol. 2021;39:787–96. Article
CAS PubMed Google Scholar * Widmark A, Gunnlaugsson A, Beckman L, Thellenberg-Karlsson C, Hoyer M, Lagerlund M, et al. Ultra-hypofractionated versus conventionally fractionated
radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial. Lancet. 2019;394:385–95. Article PubMed Google Scholar * Draulans C, van
der Heide UA, Haustermans K, Pos FJ, van der Voort van Zyp J, Boer De H, et al. Primary endpoint analysis of the multicentre phase II hypo-FLAME trial for intermediate and high risk prostate
cancer. Radiother Oncol. 2020;147:92–8. Article PubMed Google Scholar * Kishan AU, Lamb J, Casado M, Wang X, Ma TM, Low D, et al. Magnetic resonance imaging-guided versus computed
tomography-guided stereotactic body radiotherapy for prostate cancer (MIRAGE): interim analysis of a phase III randomized trial. Meeting Abstract|2022 ASCO Genitourinary Cancers Symposium.
2022. * Ma TM, Neylon J, Casado M, Sharma S, Sheng K, Low D, et al. Dosimetric impact of interfraction prostate and seminal vesicle volume changes and rotation: a post-hoc analysis of a
phase III randomized trial of MRI-guided versus CT-guided stereotactic body radiotherapy. Radiother Oncol. 2022;167:203–10. Article PubMed Google Scholar * van Schie MA, van Houdt PJ,
Ghobadi G, Pos FJ, Walraven I, de Boer HCJ, et al. Quantitative MRI changes during weekly ultra-hypofractionated prostate cancer radiotherapy with integrated boost. Front Oncol. 2019;9:1264.
Article PubMed PubMed Central Google Scholar Download references AUTHOR INFORMATION AUTHORS AND AFFILIATIONS * Department of Radiation Oncology, Radboud University Medical Center,
Nijmegen, The Netherlands Casper Reijnen, Ellen J. L. Brunenberg & Linda G. W. Kerkmeijer Authors * Casper Reijnen View author publications You can also search for this author inPubMed
Google Scholar * Ellen J. L. Brunenberg View author publications You can also search for this author inPubMed Google Scholar * Linda G. W. Kerkmeijer View author publications You can also
search for this author inPubMed Google Scholar CONTRIBUTIONS All authors contributed to the manuscript. CR and LGWK contributed to the conceptualization. CR, EJLB and LGWK contributed to
writing and revision of the manuscript, have read and have approved the final version of the manuscript. CORRESPONDING AUTHOR Correspondence to Casper Reijnen. ETHICS DECLARATIONS COMPETING
INTERESTS The authors declare no competing interests. ADDITIONAL INFORMATION PUBLISHER’S NOTE Springer Nature remains neutral with regard to jurisdictional claims in published maps and
institutional affiliations. RIGHTS AND PERMISSIONS Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with
the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable
law. Reprints and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE Reijnen, C., Brunenberg, E.J.L. & Kerkmeijer, L.G.W. Advancing the treatment of localized prostate cancer with
MR-guided radiotherapy. _Prostate Cancer Prostatic Dis_ 26, 50–52 (2023). https://doi.org/10.1038/s41391-022-00632-4 Download citation * Received: 02 October 2022 * Revised: 01 December 2022
* Accepted: 09 December 2022 * Published: 22 December 2022 * Issue Date: March 2023 * DOI: https://doi.org/10.1038/s41391-022-00632-4 SHARE THIS ARTICLE Anyone you share the following link
with will be able to read this content: Get shareable link Sorry, a shareable link is not currently available for this article. Copy to clipboard Provided by the Springer Nature SharedIt
content-sharing initiative